Starboard has approached two former Pfizer executives, Ian Read and Frank D’Amelio, to assist in its efforts, and they have ...

Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...

As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.

Pfizer in recent months has implemented aggressive cost-cutting measures to help it weather the steep decline in sales of its ...

An activist invester has taken interest in pharma giant Pfizer, which despite becoming a household name during the pandemic ...

Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...

Activist investor Starboard Value is looking to shake up pharma giant Pfizer's sagging stock price.

Citing people familiar with the matter, The Journal reported that Starboard approached former Pfizer CEO Ian Read and CFO ...

No large pharma company has traversed this decade's ups and downs quite like Pfizer. | No large pharma company has traversed ...

On top of this, Pfizer also faces key patent expirations of certain older products, and earlier estimated this will result in ...